A Texas Startup Says It Hatched Chicks from Artificial Eggs. Scientists Aren't All Cracking Open the Champagne.

On May 19, 2026, Dallas-based Colossal Biosciences announced that 26 live chickens had been hatched using 3D-printed artificial eggshells — devices the company describes as "fully artificial eggs" [1]. The chicks, ranging from a few days to several months old at the time of the announcement, represent the first time avian embryos have developed to hatching inside a non-biological shell structure under normal atmospheric conditions [2]. Colossal says the technology is a critical step toward its headline ambition: bringing back the South Island giant moa, a flightless bird that stood up to 12 feet tall and went extinct roughly 600 years ago [3].

The announcement attracted coverage from outlets including Time, NPR, National Geographic, and Nature, and was met with reactions ranging from genuine excitement to pointed skepticism [4][5][6][7]. The central question is whether this represents a meaningful advance in reproductive biology and conservation — or a well-timed press release from a company with a $10.2 billion valuation and no peer-reviewed data to show [8].

What Colossal Actually Built

The device at the center of the announcement is not what most people would picture when they hear "artificial egg." It does not contain synthetic yolk, albumen, or nutrients. It is an artificial shell — a rigid titanium lattice, shaped roughly like a soft-boiled-egg cup with its top missing, comprising about two-thirds of a natural eggshell's coverage [2]. Hundreds of hexagonal pores in the lattice allow gas exchange. The lattice is lined with a proprietary bioengineered silicone membrane, just 20 microns thick (roughly one-fifth the diameter of a human hair), designed to match the oxygen transfer capacity of a natural eggshell [2][4].

A transparent lid covers the top, allowing continuous visual observation of embryo development — a feature impossible with natural eggs [1]. The embryos themselves are still biological: fertilized chicken eggs are opened at approximately 36 to 40 hours after laying, and the yolk, albumen, and embryo are gently transferred into the artificial shell [5]. The developing chick still draws nutrients from the yolk and albumen of a real egg. Calcium, normally absorbed from the interior of a natural shell, is supplemented externally [5].

Chris Lambert, Colossal's hardware and engineering manager, told Time that evaporation control was a key engineering challenge: "A precise amount of water each day needs to exit the egg" for proper development [2].

Previous shell-less culture systems — which have existed in research labs for decades — required large volumes of pure supplemental oxygen, which damages DNA, limits scalability, and makes the systems incompatible with standard commercial incubators [1]. Colossal's main technical claim is that its membrane eliminates the need for supplemental oxygen, allowing the device to function in an ordinary incubator [1].

What "Fully Artificial" Means — and Doesn't

The phrase "fully artificial egg" in Colossal's press materials has drawn criticism from scientists who say it overstates the achievement. The device replaces the shell structure but not the egg's biological contents. As Associate Professor Nic Rawlence of the University of Otago put it, "There is no data or peer-reviewed publication associated with this announcement, just a press release and glossy video" [9].

Paul Mozdziak, a biologist at North Carolina State University, told the Smithsonian: "It could be really important, it could be fantabulous. Without data, it's really impossible to judge what the true impact is" [5]. The Smithsonian's reporting also noted that the artificial egg did not incorporate four temporary embryonic membranes normally involved in nutrition, respiration, and excretion during development [5].

Professor Amanda Black of Bioprotection Aotearoa offered a sharper assessment: "Biology is vastly more complex than what engineering can currently offer and the suggestion we can simply engineer our way out of conservation problems of our own making is an eggsaggeration" [9]. Professor Philip Seddon called it an "amazing technical feat — but it does seem to be a solution in search of a problem" [9].

Nature's coverage noted that independent scientists "range from cautious optimism about the engineering to outright rejection of the de-extinction framing" [7].

Survival Data: What We Know and Don't Know

Colossal has disclosed that 26 chicks hatched and were moved to a farm in Texas, where they are expected to live five to ten years [2]. The company has not disclosed the total number of embryos that were placed into artificial shells, the mortality rate during incubation, or any data on developmental abnormalities [5]. No comparison to conventionally hatched controls has been published. No peer-reviewed paper or preprint has been released.

Mike McGrew, an embryologist at the University of Edinburgh who serves as a Colossal advisor, acknowledged in Smithsonian reporting that previous shell-less culture systems "have not been very good" at achieving viable hatch rates [5]. Whether Colossal's system represents a significant improvement remains an open question without published data.

The company has said it plans to test the technology next with emu and ostrich embryos — larger birds whose eggs are still far smaller than what a moa egg would have been [5]. A South Island giant moa egg is estimated to have been approximately 80 times the volume of a chicken egg [1].

The Road to the Moa — and the Dodo

Colossal's artificial shell is one piece of a much larger puzzle. To produce anything resembling a moa, the company would need to: obtain or reconstruct viable moa genetic material, edit the genome of a living ratite (likely an emu) to express moa-like traits, produce embryos carrying those edits, and grow those embryos in an artificial egg large enough to support development [3][6].

CEO Ben Lamm told Time that the company has "not set a date publicly" for a moa hatching, but estimated "the mid 2030s" [2]. The dodo, Colossal's other avian target, could follow within four to five years of the moa, according to company statements [3].

Trevor Snyder, a Colossal bioengineer, explained the problem the artificial egg is meant to solve: "There's no bird on Earth today that could grow a moa embryo inside of one of their eggs. So, we have to come up with artificial eggs to be able to support those embryos" [5].

But critics question whether even a successful artificial shell gets Colossal meaningfully closer to that goal. Rawlence noted that "given the large size differences between chicken eggs and moa (up to 80 times bigger), there won't be enough yolk in living birds' eggs for the development of a giant 'moa' chick" [9]. And the resulting animal, Rawlence argued, would not truly be a moa: "They're not what I would actually call de-extinct species. They're poor facsimiles of extinct species. Extinction is still forever" [6].

The Money Behind the Mission

Colossal Biosciences was founded in 2021 by Harvard geneticist George Church and entrepreneur Ben Lamm. The company has raised more than $555 million in total funding, reaching a valuation of $10.32 billion after a September 2025 Series C extension — making it Texas's first decacorn [8][10].

Source: TechCrunch / Crunchbase

Data as of Sep 1, 2025CSV

Investors include TWG Global (the investment vehicle of Guggenheim Partners co-founder Mark Walter and billionaire Thomas Tull), filmmaker Peter Jackson, Paris Hilton, and hedge fund manager Paul Tudor Jones [8][10]. The company holds 11 registered patents and 6 trademarks [10].

This financial context matters when evaluating the announcement. Colossal is a venture-backed company with investors expecting returns. Press announcements generate media coverage and public interest, which in turn support fundraising. The absence of peer review before a coordinated media rollout — with exclusive access granted to outlets including Time and National Geographic — follows a pattern common among well-funded biotech startups, where the press release precedes the publication.

Colossal's previous claims have also drawn scrutiny. The company announced in 2025 that it had produced "dire wolf" pups, a claim some scientists disputed on the grounds that the animals were genetically modified dogs, not true dire wolves [5].

Conservation Applications — Real and Hypothetical

Supporters of the technology argue its most immediate value lies not in de-extinction but in aiding captive breeding of living endangered birds. Ben Novak, an ecologist with the conservation nonprofit Revive & Restore, told the Smithsonian: "There's an immediate group of people in zoos and conservation breeding facilities that could use this technology" [5].

Neil Gostling, a paleobiologist at the University of Southampton, was enthusiastic: "I'm genuinely blown away by it. This is brilliant. I just think it's fantastic. It's the sort of thing of science fiction" [5][6].

The potential applications include improving hatch rates for species with low reproductive success in captivity and allowing real-time monitoring of embryo development to intervene if problems arise. For species where every egg matters — such as the critically endangered kākāpō, with a global population of around 250 — even modest improvements in hatch rates could be significant.

Source: IUCN Red List / BirdLife International

Data as of Dec 1, 2024CSV

An estimated 1,300 to 1,500 bird species — roughly 12% of all bird species — have gone extinct since the late Pleistocene [5]. The rate of extinction accelerated sharply with European colonial expansion and has continued through habitat destruction, introduced predators, and climate change.

But conservation biologists have long warned against conflating de-extinction hype with practical conservation. As NYU bioethicist Arthur Caplan told the Smithsonian: "The big challenge is, what environment is this animal going to live in?" [5]. Resurrecting a genetic facsimile of a species whose habitat no longer exists does not address the ecological pressures that caused the extinction. New Zealand's Green Party responded to the moa announcement by arguing that the funding "would be better spent saving living species" [11].

The Regulatory Gap

No clear regulatory framework exists in the United States for genetically engineered animals produced for conservation release. The USDA's Animal Welfare Act governs the care of animals in research facilities, and Colossal operates under an Institutional Animal Care and Use Committee (IACUC) that reviews all research protocols [12]. The company achieved American Humane Certification for its dire wolf facility in 2025 [12].

But these are welfare standards for captive research animals, not a regulatory pathway for releasing bioengineered organisms into the wild. The FDA regulates genetically engineered animals intended for food or pharmaceutical use. The U.S. Fish and Wildlife Service (USFWS) governs the Endangered Species Act. For a genetically modified emu designed to resemble a moa, it is unclear which agency — if any — would have jurisdiction over its production, classification, or release.

Internationally, New Zealand — where Colossal intends to eventually release moa-like animals — has its own biosecurity and genetic modification regulations under the Hazardous Substances and New Organisms Act. Any release of a genetically modified organism there would require approval from the Environmental Protection Authority [9].

The regulatory ambiguity creates a risk that deployment could outpace assessment — particularly for a company with strong financial incentives to demonstrate progress.

Animal Welfare and Ethical Concerns

The ethics of de-extinction encompass several distinct concerns. The most immediate is animal welfare during the research process itself. Cloning and genetic engineering in animals have historically produced high rates of miscarriage, stillbirth, early death, genetic abnormality, and chronic disease [13]. The only successful cloning of an extinct animal — a bucardo (Pyrenean ibex) born in 2003 — had deformed lungs and survived only minutes, reportedly in significant pain [13].

Colossal has not disclosed how many embryos failed to develop during the artificial egg experiments or whether any hatched chicks showed developmental abnormalities. Without longitudinal data tracking the health, fertility, immune function, and lifespan of artificially hatched birds versus conventionally hatched controls, it is impossible to assess whether the artificial incubation process introduces developmental deficits.

A second concern is the welfare of any animal produced through de-extinction. A genetically modified bird released into an environment it did not evolve in, with no conspecifics, no learned behaviors, and possibly no suitable habitat, faces an uncertain existence. Critics argue this constitutes a form of suffering that is not detectable at hatching [13][6].

A third concern is opportunity cost. Estimates suggest that the financial resources devoted to de-extinction projects — Colossal alone has raised over half a billion dollars — could fund significant conservation efforts for currently endangered species [13][11].

Academic Interest in De-Extinction

Source: OpenAlex

Data as of Jan 1, 2026CSV

Research publications related to de-extinction have grown substantially over the past decade, peaking at over 44,000 papers in 2023 before declining [14]. This surge reflects both genuine scientific interest in gene-editing tools like CRISPR and the media attention generated by companies like Colossal. Whether the academic literature will validate Colossal's specific claims remains to be seen — the company has yet to contribute a peer-reviewed paper on its artificial egg technology.

What Comes Next

Colossal says it will scale the artificial egg for larger ratite embryos and continue its parallel work on genome editing for the moa and dodo programs. The company plans to publish its results, though no timeline has been given [1].

The scientific community's verdict is likely to hinge on that publication. The engineering achievement — a permeable membrane that supports embryo development without supplemental oxygen — is, by most accounts, genuinely impressive. Whether it constitutes an "artificial egg," whether it can scale to birds 80 times larger, and whether the entire de-extinction enterprise is a responsible use of resources are questions that remain open.

For now, 26 chickens are alive on a Texas farm. They hatched from titanium lattices instead of calcium carbonate shells, and the world is watching to see what comes next — and whether it will be a peer-reviewed paper or another press release.